Influence of Skin Subjective Symptoms on Sleep Quality in Patients with Cutaneous Disorders: A Study of 2871 Subjects

Halioua, Bruno; Miséry, Laurent; Seité, Sophie; Delvigne, V.; Chelli, Clara; Taïeb, Jacques; Taïeb, C.

doi:10.2147/ccid.s288557

Cited by 8 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Pruritus, pain and burning sensations associated with psoriatic lesions may have a direct effect on the development of sleep disturbances causing difficulties with falling asleep and awakening, 51,52 and these symptoms are thought to be the main predictors of impaired sleep together with chronic obstructive pulmonary disease and sleep apnoea. [51][52][53][54] Some reports indicate that sleep disorders are not correlated with psoriasis severity, suggesting that PASI alone cannot be used for the prognosis of sleep disorders. 55 In general, patients with moderate-to-severe psoriasis have substantial sleep impairment, and unsurprisingly, sleep impairment is strongly linked with decreased quality of life.…”

Section: System Organ Class Term Preferred Termmentioning

confidence: 99%

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice

Costanzo

Llamas‐Velasco

Fabbrocini

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundTildrakizumab (TIL) is an interleukin (IL)‐23p19 inhibitor for the treatment of moderate‐to‐severe plaque psoriasis with long‐term efficacy and safety demonstrated in Phase III trials. Studies conducted in conditions closer to clinical practice are needed.ObjectivesThe TRIBUTE study (open‐label, Phase IV) assessed the efficacy and impact on health‐related quality of life (HRQoL) of TIL 100 mg in adult moderate‐to‐severe psoriasis patients (naïve to IL‐23/Th17 pathway inhibitors) in conditions similar to clinical practice.MethodsKey efficacy measure was Psoriasis Area Severity Index (PASI). HRQoL was evaluated using the Dermatology Life Quality Index (DLQI) and Skindex‐16. Additional patient‐reported outcomes included Pain‐, Pruritus‐ and Scaling‐Numerical Rating Scale (NRS), Medical Outcome Study (MOS)‐Sleep, Work Productivity and Activity Impairment (WPAI), Patient Benefit Index (PBI) and Treatment Satisfaction Questionnaire for Medication (TSQM).ResultsOne hundred and seventy‐seven patients were enrolled (six patients did not complete the study). After 24 weeks, the proportion of patients achieving PASI scores ≤ 3, PASI 75, PASI 90 and DLQI 0/1 was 88.4%, 92.5%, 74.0% and 70.4%, respectively. Skindex‐16 overall score improved (mean absolute change from baseline, MACB [95%CI]: −53.3 [−58.1, −48.5]). Significant benefits (MACB [95%CI]) were found on pruritus‐, pain‐ and scaling‐NRS scores (−5.7 [−6.1, −5.2], −3.5 [−4.1, −3.0] and −5.7 [−6.2, −5.2], respectively), MOS‐Sleep (−10.4 [−13.3, −7.4] Sleep problems Index II) and WPAI (−36.4 [−42.6, −30.2] activity impairment, −28.2 [−34.7, −21.7] productivity loss, −27.0 [−32.9, −21.1] presenteeism and −6.8 [−12.1, −1.5] absenteeism). 82.7% of patients reported PBI ≥ 3 and the mean (SD) global TSQM score was high (80.5 [18.5]). Only one serious treatment‐emergent adverse event was reported (not‐related to TIL).ConclusionsTIL 100 mg treatment after 24 weeks in conditions close to real clinical practice showed a quick and high improvement in psoriasis signs and HRQoL. Patient reported improvements in sleep outcomes and work productivity, relevant benefits and high treatment satisfaction. The safety profile was favourable and consistent with Phase III trials.

show abstract

Section: System Organ Class Term Preferred Termmentioning

confidence: 99%

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice

Costanzo

Llamas‐Velasco

Fabbrocini

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…A recent international study involving more than 2800 people compared people with skin disease (acne, atopic dermatitis, psoriasis and chronic hand eczema) to a population without skin disease. 6 This study revealed a significantly higher prevalence of sleep disorders in patients with skin disease (71.2% vs. 32.7% in the control group of patients, p: <0.001).…”

mentioning

confidence: 51%

Insomnia in patients suffering from Hidradenitis suppurativa

Halioua,

Taieb,

Bru

et al. 2023

JEADV Clinical Practice

Self Cite

View full text Add to dashboard Cite

“…PN is one of most pruritic In the current study, weekly peak NRS scores were assessed for pruritus, burning sensation, and sleep disturbance, which are the major symptoms often associated with chronic pruritic skin diseases. 20,21 All of these symptoms were worsened with increasing disease severity, with pruritus This suggests that controlling pruritus might be the key to improving treatment satisfaction in patients with PN.…”

Section: Discussionmentioning

confidence: 99%

Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan

Murota,

Arima,

Yoshida

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Prurigo nodularis (PN) is a chronic inflammatory skin disorder with a high disease burden. In this cross‐sectional, web‐based survey, Global Questions (GQ), the Numerical Rating Scales (NRS) for pruritus, burning sensation and sleep disturbance, the Short‐Form‐8 (SF‐8) Health Survey, Dermatology Life Quality Index (DLQI), Patient Health Questionnaire 9 (PHQ‐9), Work Productivity and Activity Impairment (WPAI), and Treatment Satisfaction Questionnaire for Medication–9 (TSQM‐9) scores were used to assess the current disease burden and treatment satisfaction among patients with PN in Japan. In total, 97 patients were included (55.7% male, median age 51 years, median duration of PN 36 months). Based on GQ scores, 35.1% of patients had mild disease, 50.5% moderate, and 14.4% severe disease. Disease burden increased as the severity of PN increased, as indicated by worsening of pruritus NRS scores and quality of life (DLQI, PHQ‐9, WPAI presenteeism, work productivity loss, and activity impairment scores). Patients with comorbid atopic dermatitis (AD) also had more intense pruritus than those without AD. Mean ± standard deviation TSQM‐9 scores for effectiveness, convenience, and global satisfaction were 54.7 ± 18.1%, 62.4 ± 15.2%, and 57.4 ± 15.9%, respectively. TSQM‐9 scores were lowest in patients receiving the most intensive guideline‐directed treatment (i.e., topical corticosteroids + systemic oral corticosteroids or cyclosporine), highlighting an unmet need for more effective treatment options for patients with PN. In summary, Japanese patients with PN reported increased disease burden and reduced treatment satisfaction with increased disease severity, despite the use of guideline‐recommended therapies.

show abstract

Influence of Skin Subjective Symptoms on Sleep Quality in Patients with Cutaneous Disorders: A Study of 2871 Subjects

Cited by 8 publications

References 56 publications

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice

Insomnia in patients suffering from Hidradenitis suppurativa

Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan

Contact Info

Product

Resources

About